Goldberg Law PC ( announces that it is investigating CytRx Corporation ("CytRx" or the "Company") (Nasdaq: CYTR) concerning possible violations of federal securities laws.

If you purchased or otherwise acquired CytRx shares and would like more information regarding the investigation, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm's website at, or by email at

The investigation concerns whether the Company violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Specifically, the investigation will focus on the July 12, 2016 announcement of the results of the Company's Phase 3 clinical trial of aldoxorubicin, which did not show any improvement from other commonly used cancer drugs. CytRx stated that nearly half of the patients in the Phase 3 trial were excluded from the data since the study was disturbed by a partial clinical hold on November 2014. When this news was announced, stock prices dropped sharply.

If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at, or email us at

Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on

Copyright Business Wire 2010